U.S. Intravenous Solutions Market to Grow Strongly with Rising Demand for IV Therapy

The U.S. intravenous solutions market size accounted for USD 5.82 billion in 2025 and is predicted to increase from USD 6.19 billion in 2026 to approximately USD 10.82 billion by 2035, expanding at a CAGR of 6.4% from 2026 to 2035. Increasing demand for intravenous solutions due to increasing chronic diseases and geriatrics, rise in medical technology, home medical care expansion, and oncology care requirements.

What are Intravenous Solutions?

IV solutions are particularly intended liquids that are injected into a vein to prevent or manage dehydration. IV fluid restores fluid to the intravascular spaces, and these IV fluids are used to enable the shift of fluid among compartments because of osmosis. There are three types of IV fluids: hypotonic, isotonic, and hypertonic. It especially articulates liquids that are injected into the vein to prevent or manage dehydration. Intravenous services are applied to replace fluids, electrolytes, and nutrients in patients who cannot take them orally. IV fluids are administered for different reasons, such as resuscitation, improvement of electrolyte imbalances, or in more significant cases.

Recent Advancements in Hormone Replacement Therapy:

Intravenous fluid therapy plays a significant role in modern healthcare practice, specifically in intensive care management. Recent developments in IV fluid therapy emphasize adapted care and evidence-based protocols. As research and technology advance, IV fluid therapy continues to evolve, improving its role in patient-centred care and enhancing results in diverse healthcare conditions. IV fluid therapy is a keystone in the helpful care of pancreatic disorders, specifically in acute pancreatitis, where timely and carefully managed fluid resuscitation enhances healthcare results and lowers morbidity.

Market Segmentation Overview

• By product type, the crystalloids segment contributed the largest U.S. intravenous solutions market share of 72% in 2025, as crystalloids are most often preferred because of their ease of administration and reduced challenges of allergic reactions. They are applied for growing the intravascular volume in conditions such as hypotension, dehydration, and sepsis. The capability of crystalloids to pass through the capillary endothelium.
• By nutritional content, the non-nutritional IV solutions segment contributed the largest market share of 68%, this type of intravenous solutions those significantly used for fluid resuscitation, medicine delivery, or electrolyte management, rather than offering caloric intake, provides various significant healthcare and therapeutic benefits. This therapy delivers significant antioxidants such as glutathione and vitamin C, which support removing toxins and preventing cell injury.
• By volume, the large volume parenterals (LVP) segment contributed the largest U.S. intravenous solutions market share of 64% in 2025, as LVPs are applied in hospitals, clinics, and long-term care services for different purposes, like rehydration and medicine administration. LVPs are sterile provisions of 250 ml or greater that are directed parenterally.
• By end user, the hospitals segment contributed the largest market share of 58% in 2025, as parenteral nutrition gives the gastrointestinal system a chance to heal from severe illness or surgery.  Intravenous (IV) administration offers instant drug effects, which is significant for emergencies such as cardiac arrest and anaphylaxis.

Top Companies in the U.S. Intravenous Solutions Market

The top five organizations in this group dominate the U.S. intravenous solutions market. Meanwhile, Baxter International Inc. it is wide portfolio of IV fluids, nutrition, and innovative safety containers. B. Braun Melsungen AG offers high-quality IV solutions, specifically in fluid management, drug delivery, and healthcare compounding. Fresenius Kabi AG, it provides a wide range of IV fluids with noteworthy manufacturing capacity. ICU Medical Inc., it includes health insurance, 401K/retirement plan, and employee stock purchase plan. Otsuka Pharmaceutical Co. produces and sells inorganic salts as raw materials for I.V. solutions.

Segments Covered in the Report

By Product Type

• Crystalloids
  • Normal Saline
  • Lactated Ringer’s Solution
  • Dextrose Solutions
    • D5W
    • D10W
  • Others 
• Colloids
  • Albumin Solutions
  • Hydroxyethyl Starch (HES)
  • Gelatin-based Solutions
  • Dextran Solutions

By Nutritional Content

• Parenteral Nutrition Solutions 
  • Total Parenteral Nutrition (TPN)
  • Peripheral Parenteral Nutrition (PPN)
• Non-nutritional IV Solutions

By Volume

• Small Volume Parenterals (SVP)
  • ≤100 ml
• Large Volume Parenterals (LVP)
  • 100 ml

By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Plastic Bottles

By Packaging Type

• Flexible Bags
• Glass Bottles
• Plastic Bottles

By Distribution Channel

• Direct Sales
• Group Purchasing Organizations (GPOs)
• Retail & Online Pharmacies